Development of a UPLC-MS/MS method for the determination of lacosamide and its metabolite and its application to drug-drug interaction

Lacosamide, a third-generation novel antiepileptic drug, was first approved in 2008 as an adjunct to partial seizures. In 2014, the U.S. Food and Drug Administration (FDA) approved it as a single agent for partial seizures. Since epilepsy is a chronic condition, most patients need long-term antiepil...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jie Chen, Yuxin Shen, Hailun Xia, Xiaohai Chen, Ren-Ai Xu, Guanyang Lin, Gexin Dai
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2023-11-01
Colecção:	Frontiers in Pharmacology
Assuntos:	methodological verification lacosamide UPLC-MS/MS interaction pharmacokinetic
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1265252/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!